Great get in Korea by Flagship

Senate passed the Biosecure Act Thursday evening as amendment to the National Defense Authorization Act. It's not in House version, but @steveusdin1 Usdin says it's likely to be included in the final version that President Trump will sign by year-end:

.@WSJ: "Stuart Anderson at the National Foundation for American Policy has looked at the three science Nobels awarded since 2000, and immigrants make up 40% of the U.S. winners. As the nearby chart shows, it’s 45% for physics, 43% for chemistry and 32% for medicine." just sayin'

The biotech industry lost a giant last month, when David Baltimore passed away. I spoke to some of his closest friends and colleagues and wrote this remembrance (in front of our paywall). David Baltimore's enduring legacy: Remembering 'a giant of science’

Peter Marks has joined @EliLillyandCo as SVP for molecule discovery and head of infectious diseases, marking his return to industry after nearly a decade at @US_FDA, per @BioCentury's @steveusdin1

Seeing opportunities among headwinds, TCG X closes $1.3B 3rd fund: @BioCentury's @BioBonanos speaks with Chen Yu, who sees attractive valuations in private and public equities that could turn into strong returns and draw LPs back into biotech. Read now:

And they're off: Amid shutdown, disruption, @IamBiotech, @PhRMA slated to meet with @US_FDA leadership to discuss PDUFA reauthorization. Execs are split in 3, says @SteveUsdin1: BIO (incremental change), PhRMA (minimal) & a 3rd group (major overhaul)

Bad Bunny, the halftime performer for this Superbowl, is an Eagles fan 👀

.@US_FDA's Tidmarsh seems 2 be pursuing a personal agenda, with LI posts like the 1 that drove $AUPH lower. Under previous administrations, a CDER director who behaved this way would have been ordered to pack up and leave, writes @BioCentury's @steveusdin1

Scoop via @BioCentury's @steveusdin1: @CMSGov to propose 'most favored nation' pricing benchmark model. White House reviewing proposed international reference pricing model

FDA approves Stealth Biotherapeutics' Forzinity, first treatment for Barth Syndrome

Restricting U.S. in-licensing from China could spark a global IP arms race, hurting patients and U.S. biotech companies, @NEA's @ScottGottliebMD warns. via @BioCentury's @steveusdin1

$LBRX's IPO 1st to raise >$25M by a pure-play biopharma on @Nasdaq since $AARD in February & at $285M it's 2nd largest of '25 after $MTSR. @LB_pharma finishes the day up 12%.

House passes bill seeking to end most U.S.-China academic research collabs. @steveusdin1 says like Biosecure, the SAFE Research Act is part of a trend in DC to re-define nat security to include basic, applied research on topics such as cancer

U.K. nds to find common ground with pharmas on reimbursement if it wants to win the competition for life sciences investments. Fortunately for @MHRAgovuk CEO Lawrence Tallon creating a world-class reg environment, is less contentious. via @SteveUsdin1

On latest #BioCenturyThisWeek pod: @BioBonanos on @JMaraganore, Meanwell newco to develop AI guided early risk assessment tool for CV, @SteveUsdin on @US_FDA's Prasad disrupting vax status quo & @FishburnSimone's take on resilience in biotech & tennis, @usopen & @naomiosaka

Amy Peterson is out as CMO of @ExelixisInc. The cancer company named Dana Aftab, who was EVP, discovery and translational research and CSO, EVP R&D

A rare biotech filing for a NASDAQ IPO appeared late Friday from LB Pharmaceuticals Inc. The neuro play has raised $122M to date; top shareholders include Deep Track Capital, Vida Ventures, Pontifax and TCG Crossover. h/t @BioBonanos

After delays & an about-face on reconsidering a CRL, @US_FDA will now conduct exceptionally quick review of Stealth BioTherapeutics' treatment for #Barthsyndrome. Does the move signal the agency's changing stance on rare disease therapies? via @BioBonanos

Just when u thought it was safe to go back in the water - it's baaack. Sens. reviving Biosecure via an amendment in must-pass Defense bill that seeks disengagement with Chinese biotechs, attempts to address concerns that killed Biosecure. via @steveusdin1